Â鶹´«Ã½É«ÇéƬ

Glycosylation is a frequent post-translational modification, and the resulting glycoproteins — proteins decorated with carbohydrates — are involved in many functions that influence proteins’ physical and immunological properties. This means researchers need software that correctly characterizes glycosylation and identifies the types of glycoproteins involved.

Two important types of glycoproteins are O-linked and N-linked, so called because sugars are attached to the protein through an oxygen atom (O) or nitrogen atom (N) of the residues they bind to. Researchers have limited knowledge about protein glycosylation, especially O-glycosylation. According to Zsuzsanna Darula, head of the Single Cell Omics Advanced Core Facility at the Hungarian Center of Excellence for Â鶹´«Ã½É«ÇéƬ Medicine, or HCEMM, that’s due to a number of factors: “their impressive heterogeneity, the inability to predict which residues may be modified, the identified modification sites are not always occupied, and several, rather different glycans may modify the same residue.”

Mass spectrometry, a valuable tool for discovering protein modifications, works by measuring the mass of an intact molecule and then fragmenting the molecule and measuring its pieces to decipher its chemical structure. Using the latest mass spectrometers with improved mass accuracy and detection sensitivity, Adam Pap and collaborators at the Biological Research Centre and HCEMM analyzed the largest intact human O-glycopeptide data set to date from human urine samples.

In the lab’s initial analysis, Pap noticed that the urinary O-glycosylation landscape was more complicated than expected. The team ran the data through four automated interpretation search engines and also characterized it manually. They noticed large discrepancies among the search engine data interpretations, which in the journal Â鶹´«Ã½É«ÇéƬ & Cellular Proteomics.

The team originally had hoped to identify O-glycosylation differences between healthy individuals and cancer patients and, thus, potential biomarkers of bladder cancer. Instead, “We discovered in the process that our tools are not good enough yet for that purpose,” Darula and Pap wrote in an email, “and we focused on the shortcomings and necessary improvements of data interpretation software.”

More than half of the O-glycopeptides were picked up by only one of the four search engines, and some N-glycopeptides even qualified as O-glycosylation candidates, according to certain software. Only about 20% of the identifications were supported by three or four of the programs.

Glycopeptides are tricky to characterize. A researcher must determine both the sequence of the peptide and the number and composition of the individual modifying glycans, as well as their attachment sites. The authors recommend applying two fragmentation methods during the analysis: higher-energy collision-induced dissociation, or HCD, and electron-transfer dissociation and HCD in combination. The resulting spectra must be used in concert for the data interpretation.

According to Darula and Pap, the team’s secret weapon was inspecting the data themselves, and in doing so they reported about 35 novel structures.

“Our study should be a warning for both the scientific community and the general public that we all want an easy and quick answer to most of our questions and for this reason, we throw our critical thinking aside and trust the computers too much,” they wrote.

Darula and her team urge closer collaboration between software developers and mass spectrometry groups to improve the code accuracy in glycopeptide assignments.